Kromek Share Discussion Threads

[btgman] 26/10/2021 07:29

This books revenue for years. Exactly what an acquirer will be looking for.

AIMHO
GLA
BTG

[dougmachin] 26/10/2021 07:22

This is a huge contract, totally agree.

QP - You're clutching at straws now IMO.

DM

[btgman] 26/10/2021 07:15

Fantastic news for Kromek this contract supports Cenkos price target of greater than 50p. It is noted that 21/22 broker turnover was forecast as £15m. This is a huge contract.

AIMHO
GLA
BTG

[quepassa] 26/10/2021 07:11

Another "UP TO" contract.


Come on, why don't they just say how much the initial concrete order amount is for.

UP TO $15m over seven years

Annualised equals $2.142pa = £1.56m pa (UP TO).


As always, no mention of the counterparty.

Who can say/know guess what "UP TO" means.

ALL IMO. DYOR.
QP

[strategicinvestor2] 25/10/2021 21:01

Kromek exhibiting in US, Spain and UK in coming days. Positive to see them out there.

[b00mb0y] 22/10/2021 17:33

“Status Quo” down down deeper and down.
KMK share price “ down down deeper and down.

Status quo- the current state of affairs

[aqc888] 21/10/2021 14:54

Do you remember Neil Woodfords fund that invested in a company called Industrial Heat? It was a big embarrassment. Co-investors were Hollywood widows and the guy running it had a dubious scientific reputation with various allegations. Anyway, it caused much embarrassment, many questions about his due diligence and caused faith in his expertise to be damaged. My point with Kromek not having any institutional investors is that it’s a bit of a worry. Fund managers either see it as a poor company, or a risk of it blowing up in their faces causing embarrassment. Or it’s a great opportunity for small private investors to exploit an area larger players don’t want to touch because if it’s dubious claims.

[dougmachin] 21/10/2021 14:34

Even these so called institutions are full of individuals making decisions.

I would say better to trust some PIs who have made their own decisions with their own hard earnt cash, than institutions that can employ staff that can just walk away.

Institutions that are playing with other people's money.

Give me the Newlands over institutions and their phat fees any day.

Also, from all these institutions (or PIs through these institutions if that's what you want to call them) + the Newlands, they can't all be inexperienced dim-wits.

Major Shareholders Shares %
Hargreaves Lansdown Asset Mgt 53,871,188 12.47
Interactive Investor 50,946,414 11.80
Canaccord Genuity Group Inc 35,994,999 8.34
Halifax Share Dealing 26,511,039 6.14
Polymer Holdings 21,940,142 5.08
Herald Investment Mgt 21,080,059 4.88
Barclays Wealth 15,234,612 3.53
A J Bell Securities 14,929,617 3.46

I agree though BTW, Kromek, give us some more news pleaseeeeeee.

DM

[dougmachin] 21/10/2021 12:47

IMO...
- There's some element of truth in what AQC888 is saying, I would prefer more "delivery" from KMK for sure.
- But those moaning on about what you consider to be a bad investment, certainly not my style.
DM

[aqc888] 21/10/2021 12:05

Could you post the thread number regarding my expectation Kromek should design and test the prototype in 3months?

[33mick] 21/10/2021 11:35

Well AQC888 we've already touched on 'Factual' posts some months ago....I seem to remember when you were upset Kromek hadn't managed to design and test prototype's in 3 months? Then upset that they hadn't sold any, even though they weren't for sale.
Recently you've banged on about no serious investors in Kromek...I suppose the Newlands 13 million shares holding by them is not relevant. Many would disagree. Now you're stating as fact that Kromek have mislead the market ..ugh...Arnab has been updating on the potential market of CZT and the step change in hospital imaging and low dose etc.
just as the article I saw a few days ago mentions....that's the first press article I've seen ever stating this....you ought to do some research on the company's you invest in...most people do and they don't get so wound up when things dont majicaly happen to some self invented time lines.

[aqc888] 21/10/2021 10:02

Mick33, these discussion boards are for debate. We should be able to dismantle each other’s points. Put forward our own proposition and everyone can make their own minds.

Just saying he’s “not factual” and copy and pasting a Daily Mail snippet isn’t really helpful. I’d quite like to hear why my points are overly pessimistic. Might persuade me to buy back the shares I’ve sold.

[33mick] 21/10/2021 09:14

Anyone who interested in a more "Factual" account of the Hospital X-ray scanner market might find this interesting...
Kromek's CZT state of the art development work seems to me to very well placed to benefit from this upcoming wave of global requirements in colour 3D imaging tech.

NHS scanners and x-ray machines are at least ten years old at more than a quarter of health trusts.

"Great Ormond Street Hospital Trust has a 21-year-old CT scanner"

[b00mb0y] 21/10/2021 08:55

Regardless of whether he has sold or not he is just venting his utter frustration and anger as I have done for many months now. Everything he has said is 100% correct. As I have said earlier, if we don’t get a brake-out soon then we could be looking at a worse case scenario of .04p by end of year. Hope not though.

[strategicinvestor2] 21/10/2021 08:28

Have you sold ? With these risks there must be many other better companies in the thousands to chose from in the market. Good luck with wherever you reinvest. Cheers

[aqc888] 20/10/2021 23:07

It’s my view that even if Kromek are successful with the biological pathogen detectors - the management will utterly squander the opportunity.

Just like they have done with the hospital scanners. Their only rival was just bought for £200m+ while Kromek are struggling to stay afloat with a market cap of £60m. Nobody wants to touch Kromek.

The CEO doesn’t want any shares. Buyers of CPZ scanner businesses don’t want to buy Kromek- even when it’s less than half price. No institutions want any Kromek shares. Nobody wants any Kromek shares except the CEO and his shameful £2,513 purchase and the pathetic attempt of the Chairman to inspire confidence by purchasing £15k. Utterly hopeless. So much potential that is totally wasted. Makes me so irritated. But could so easily be reversed with a clear out.

[aqc888] 20/10/2021 08:03

Being paid £300k+ and buying less than £10k of shares at the last fundraising is shameful. He should leave his job. He has no confidence in Kromek. Kromek investors have no confidence in him. He needs to go ASAP

[aqc888] 20/10/2021 07:46

This CEO will continue to destroy value. Will continue to raise expectations and not deliver. He’s not the right man for the job and is paid far too much for the failure he has presided over.

He should be totally embarrassed at his tiny shareholding, his unwillingness to stay level at the last £13m fundraising and his constant inability to meet his own targets. No problem with him receiving £300k+ if he wasn’t simultaneously begging for more money from shareholders to stay afloat. He should be ashamed of himself. This shameful governance needs to end

[ark87] 20/10/2021 01:10

The very first RNS was 8 years ago. Raised £15 million at 51p - That's a lot of time to implement his strategy. How well do we think Arnab has done?

Kromek Group Plc

Admission and First Day of Dealings on AIM - 16th Oct 2013

The Company has raised £15 million before expenses through the sale of new ordinary shares at a price of 51 pence per share in an oversubscribed fundraising. At admission, the Company will have a total of 107,607,335 ordinary shares in issue.

The proceeds of the fundraising will be used for product development, expansion of the sales and marketing team, investment into the Company's intellectual property portfolio, capital expenditure to support future growth and manufacturing capability, working capital and strengthening the balance sheet, including paying down outstanding loans.

Arnab Basu, CEO, commented: "We are delighted with our oversubscribed fundraising. After many years developing the business and our technology, Kromek is ready to begin harvesting value by seizing the opportunities to sell our technology and products into the medical imaging, security screening and nuclear detection markets.

He added, "With the proceeds of the IPO, we will invest in the company's IP portfolio and manufacturing capabilities, whilst accelerating our commercial activities in our chosen markets. We will continue to develop relationships with some of the world leading companies in our target sectors. We welcome our new shareholders and I look forward to working with them in order to achieve Kromek's full potential."